Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18α-glycyrrhizin is an epimer of glycyrrhizic acid, a triterpenoid saponin and one of the main bioactive constituents found in licorice (Glycyrrhiza species)[2][6]. It is structurally similar to the more common 18β-glycyrrhizic acid but differs in stereochemistry at the C-18 position. While glycyrrhic acids are well known for their anti-inflammatory, antiviral, antiallergic, and hepatoprotective properties[3][5], the α-isomer (18α-glycyrrhizin) has been reported to have weaker antihepatotoxic and anti-inflammatory activities compared to its β counterpart[1][10]. The mechanism of action for glycyrrhic acids generally involves suppression of pro-inflammatory cytokines such as TNF-alpha, inhibition of NF-kB translocation into nuclei, free radical scavenging activity, and modulation of immune cell proliferation via JNK/ERK/PI3K-AKT pathways[3]. The presence of natural 18α-glycyrrhizin in licorice extracts is debated; it can be produced by epimerization from the β form under alkaline conditions but may also exist as a minor natural congener[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18α-glycyrrhizin.